Please login to the form below
aclidinium
This page shows the latest aclidinium news and features for those working in and with pharma, biotech and healthcare.
Circassia exits allergy R&D after placebo effect strikes again
Circassia also recently formed a partnership with AstraZeneca (AZ) for the development and commercialisation of two chronic obstructive pulmonary disease (COPD) medicines - Tudorza (aclidinium bromide) and Duaklir (aclidinium bromide/formoterol) in
Latest news
-
GSK's triple COPD therapy tops Symbicort in phase III trial
These include GSK's Relvar/Breo (vilanterol/fluticasone furoate) and Anoro (vilanterol/umeclidinium bromide), as well as Novartis' Ultibro (glycopyrronium/indacaterol), AZ's own Duaklir (aclidinium bromide/formoterol fumarate) and Boehringer
-
GSK brings forward triple COPD therapy filing in US
GSK is jostling for market share with other two-drug combinations, however, including Novartis' Ultibro (glycopyrronium/indacaterol), AstraZeneca's Duaklir (aclidinium bromide/formoterol fumarate) and Boehringer Ingelheim's Spiolto
-
Boehringer bags FDA approval for Spiriva-based combo
AstraZeneca is also bringing its aclidinium bromide/formoterol fumarate product -sold in Europe as Duaklir - through the latter stages of development.
-
GSK sees COPD future in triple therapy
Duaklir (formoterol fumarate and aclidinium bromide) jostling for market share.
-
AZ adds to respiratory portfolio with Actavis drugs
It follows a similar deal agreed in July last year for AZ to buy the global respiratory portfolio of Almirall for $2bn, including the approved Eklira (aclidinium) for COPD and several ... Tudorza Pressair (aclidinium bromide inhalation powder) is a
More from news
Approximately 2 fully matching, plus 31 partially matching documents found.
Latest Intelligence
-
Interview: Jorge Gallardo, Almirall
We now have five R&D projects about to start or already in phase III and we are intending to register another two projects in 2011: aclidinium bromide for chronic obstructive
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
- Strategic Planner, Healthcare Advertising
-
£47, 000 – £53, 000
- Senior Project Manager - Medical Writing
-
Great salary and bebefits
- Home based, Editorial Team Leader, Medical Communications
-
Excellent package
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
-
Senior Account Manager
-
Competitive salary commensurate with experience
- Home based, Chief Medical Writer, Medical Communications
-
Excellent package
- Business Unit Head, Medical Communications, London
-
Excellent package
- Account Director, Medical Communications
-
C£50 – 65, 000 benefits and bonus
-
Client Services Director - Med Comms
-
Great salary and bebefits
- Home based, Principal Medical Writer, Medical Communications
-
Excellent package
-
Account Manager
-
£40, 000 - £45, 000 benefits
- Multi-Channel Account Managers - Road / Homebased – Full or Part...
-
Competitive salary
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
- Account Director, Consumer Healthcare PR, Global PR agency
-
£50, 000 – £58, 000
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
Subscribe to our email news alerts
- Communiqué Awards 2018: Photo Gallery - Communiqué Awards 2016
- NHS England says yes to Roche's Hemlibra
- Moving annual total (MAT)
- Vertex to Theresa May: Orkambi verdict ‘threatens bio investment’
- GSK sells eczema and psoriasis drug to Dermavant for £250m
- Communiqué Awards 2018: Winners in pictures - Communiqué Awards 2016
- May’s Brexit plan cautiously welcomed by biopharma sector
- Daily Brief: Novartis exits anti-infectives drive, Hancock takes over from Hunt and Trump attacks 'soft Brexit' plan
- GSK sells eczema and psoriasis drug to Dermavant for £250m
- Fishawack acquires brand communications agency Healthcircle
- Roche keeps Venclexta train rolling with new leukaemia filing
- Pfizer builds gap between pharma and consumer health units
PMHub
Ashfield
Transforming healthcare outsourcing. From small beginnings in 1997, Ashfield has grown rapidly into an international healthcare services organisation. By anticipating...
Latest intelligence
- Digital trends in B2B sales - how far behind is Pharma?
- The modern approach to B2B sales is data-driven, and enabled by digital tools....
- The rise of vertical integration in the US payer landscape
- Is it a solution to addressing the challenges of the value-based marketplace?...
- Creativity has lost its worth
- Creativity has lost its worth, and sadly it is undermining effectiveness...
Quick links
Infographics
